心血管疾病基因编辑治疗:2026 ACC科学声明
该科学声明由美国心脏病学会发布,面向临床医生概述心血管疾病基因编辑治疗的基础科学、当前最适合 initial 应用的心血管疾病(如某些高胆固醇血症和淀粉样变性等单基因病、可通过敲低蛋白生产修饰且蛋白合成错误发生在肝脏的疾病),以及基因编辑固有的挑战(包括高成本一次性治愈的社会与伦理影响)。声明指出基因编辑技术进步迅速,某些心血管疾病的治愈性治疗即将到来,心血管临床医生应确保这些干预措施以 proper 临床适应证应用并设置护栏以促进伦理和公平治疗。
要点
- 基因编辑治疗在心血管疾病中进展迅速,某些单基因心血管病的治愈性治疗即将到来。
- 当前最适合 initial 应用的是单基因病、可通过敲低蛋白生产修饰且蛋白合成错误发生在肝脏的疾病,如某些高胆固醇血症和淀粉样变性变异。
- 脂质纳米颗粒为肝细胞表达治疗靶点的心血管疾病提供了有前景的递送方法。
核心结论
- 基因编辑技术进步迅速,某些心血管疾病的治愈性治疗即将到来,临床医生需确保其以 proper 临床适应证和伦理护栏应用。
研究设计与样本
- 美国心脏病学会科学声明,面向执业临床医生概述心血管疾病基因编辑治疗。
主要发现
- 基因组测序进步使基因检测率大幅提高、可及性改善且成本降低。
- CRISPR-Cas9相关方法使精确靶向编辑患者基因组成为可能。
- 脂质纳米颗粒为肝细胞表达治疗靶点的心血管疾病提供了有前景的递送方法。
- 当前最适合 initial 应用的是单基因病、可通过敲低蛋白生产修饰且蛋白合成错误发生在肝脏的疾病,如某些高胆固醇血症和淀粉样变性变异。
临床怎么用
- 心血管临床医生应了解基因编辑治疗的基本科学及其在当前最适合的心血管疾病中的应用。
- 应用基因编辑干预时应确保 proper 临床适应证并设置伦理和公平治疗护栏。
局限性
- 基因编辑面临特异性、安全性和高效递送至 desired 细胞的挑战。
- 高成本一次性治愈带来社会和伦理影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
It is increasingly recognized that many cardiovascular diseases have a genetic basis. Advancements in genome sequencing have allowed for dramatically higher rates of genetic testing with improved availability at a reduced cost. Technologic innovations-catalyzed by clustered regularly interspaced short palindromic repeats (CRISPR)-associated protein 9 (Cas9)-related approaches-have enabled the ability to edit an individual patient's genome in a precise and targeted manner. Delivery of these genetic interventions to desired cells specifically, safely, and efficiently has been a challenge, but the development of lipid nanoparticles offers a promising approach in cardiovascular diseases with hepatocyte-expressed treatment targets. Progress in genetic therapies have been exponential such that curative treatments for some cardiovascular diseases are imminent. Given such rapid advancement and the potential scope of impact, this scientific statement provides an overview of gene editing therapies for the practicing clinician. This includes descriptions of: 1) the basic science that supports gene editing therapy; 2) the cardiovascular diseases that are currently most amenable for initial application of gene editing-diseases that are typically monogenic, that are modifiable by knockdown of protein production, and whose protein synthesis errors occur in the liver (certain variants of hypercholesterolemia and amyloidosis); and 3) the inherent challenges of gene editing including the societal and ethical implications of high-cost, single-treatment cures. As gene editing technology in the treatment of cardiovascular diseases continues to expand and evolve, cardiovascular clinicians are key stakeholders in ensuring that these interventions are applied with the proper clinical indications and with guardrails to promote ethical and equitable treatment.
引用
- Ambardekar AV, Bhatt A, Hoekstra M, et al. Gene Editing Therapy in Cardiovascular Disease: 2026 ACC Scientific Statement: A Report of the American College of Cardiology. J Am Coll Cardiol. 2026. PMID: 41885675. doi:10.1016/j.jacc.2026.02.5092
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。